Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab vs FOLFOX in Advanced Biliary Tract Cancer
NCT06529718Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ivonescimab in biliary tract cancer (BTC) (2 arms), sponsored by Unicancer. Primary endpoint: Progression-free survival up to 4 years. Started Oct 2025; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06529718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06529718.